All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Activin E, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Kyle Moran, all published on August 4, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Kyle Moran
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Activin E, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Kyle Moran, all published on August 4, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Kyle Moran. Shared-story counts are live from our verified record — not editorial picks.
Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
